Forge partnership to develop AI-designed enzymes for genetic medicine
Profluent, an AI-focused company, has announced a research agreement with Eli Lilly aimed at developing AI-designed enzymes to treat genetic diseases. The partnership could be valued at up to $2.25 billion.